Zoetis Inc. $ZTS Shares Sold by Naviter Wealth LLC

Naviter Wealth LLC lessened its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 10.4% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,826 shares of the company’s stock after selling 212 shares during the quarter. Naviter Wealth LLC’s holdings in Zoetis were worth $285,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ZTS. Nova Wealth Management Inc. acquired a new stake in Zoetis during the 1st quarter worth approximately $25,000. 1248 Management LLC purchased a new position in Zoetis in the 1st quarter worth approximately $27,000. Saudi Central Bank purchased a new position in Zoetis in the 1st quarter worth approximately $29,000. Cornerstone Planning Group LLC boosted its holdings in Zoetis by 79.3% in the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock worth $30,000 after acquiring an additional 88 shares during the period. Finally, REAP Financial Group LLC boosted its holdings in Zoetis by 201.5% in the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after acquiring an additional 131 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

ZTS stock opened at $143.45 on Wednesday. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The firm has a market cap of $63.58 billion, a P/E ratio of 24.69, a P/E/G ratio of 2.28 and a beta of 0.90. Zoetis Inc. has a 12-month low of $139.34 and a 12-month high of $196.55. The stock’s 50 day simple moving average is $148.98 and its 200 day simple moving average is $154.11.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.14. The business had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business’s revenue was up 4.2% compared to the same quarter last year. During the same period in the prior year, the company posted $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities research analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be given a $0.50 dividend. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 annualized dividend and a yield of 1.4%. Zoetis’s dividend payout ratio (DPR) is currently 34.42%.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on ZTS shares. Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. Argus restated a “buy” rating and issued a $190.00 price target on shares of Zoetis in a report on Tuesday, September 9th. Leerink Partnrs cut Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Leerink Partners cut Zoetis from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Finally, Stifel Nicolaus cut Zoetis from a “buy” rating to a “hold” rating and reduced their target price for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Four investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $196.71.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.